

業績目録

Peer reviewed publications

1. Silva AN, Coffa J, Menon V, Hewitt LC, Das K, Miyagi Y, Bottomley D, Slaney H, Aoyama T, Mueller W, Arai T, Tan IB, Deng N, Chan XB, Tan P, Tsuburaya A, Sakamaki K, Hayden JD, Yoshikawa T, Zondervan I, Savola S, Grabsch HI. Frequent coamplification of receptor tyrosine kinase and downstream signaling genes in Japanese primary gastric cancer and conversion in matched lymph node metastasis. *Annals of Surgery* 2017; in press
2. Yabushita Y, Mori R, Taniguchi K, Matsuyama R, Kumamoto T, Sakamaki K, Kubota K, Endo I. Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer. *Anticancer Research* 2017; 37(5): 2465-2476.
3. Katayama Y, Oshima T, Sakamaki K, Aoyama T, Sato T, Masudo K, Shiozawa M, Yoshikawa T, Rino Y, Imada T, Masuda M. Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy. *In Vivo* 2017; 31(4): 565-571.
4. Ogino I, Watanabe S, Sakamaki K, Ogino Y, Kunisaki C, Kimura K. Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer. *Strahlentherapie und Onkologie*. 2017; 193(7): 552-560.
5. Chikamoto A, Inoue R, Komohara Y, Sakamaki K, Hashimoto D, Shiraishi S, Takamori H, Yamashita Y, Yoshida N, Yamanaka T, Yamashita Y, Baba H. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. *Annals of Surgical Oncology* 2017; 24(7): 2040-2046.
6. Nishiguchi S, Sugaya N, Sakamaki K, Mizushima S. End-of-life care bonus promoting end-of-life care in nursing homes: An 11-year retrospective longitudinal prefecture-wide study in Japan. *BioScience Trends* 2017; 11(1): 54-61.
7. Nakahashi H, Kosuge M, Sakamaki K, Kiyokuni M, Ebina T, Hibi K, Tsukahara K, Iwahashi N, Kuji S, Oba MS, Umemura S, Kimura K. Combined impact of chronic kidney disease and contrast-induced nephropathy on long-term outcomes in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention. *Heart and Vessels* 2017; 32(1): 22-29.
8. Higuchi A, Oshima T, Yoshihara K, Sakamaki K, Aoyama T, Suganuma N, Yamamoto N, Sato T, Cho H, Shiozawa M, Yoshikawa T, Rino Y, Kunisaki C, Imada T, Masuda M. Clinical significance of platelet-derived growth factor receptor- β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy. *Oncology Letters* 2017; 13(2): 905-911.
9. Fujita Y, Iwasaki A, Sato T, Fujisawa T, Sekino Y, Hosono K, Matsushashi N, Sakamaki K,

- Nakajima A, Kubota K. Feasibility of endoscopic papillary large balloon dilation in patients with difficult bile duct stones without dilatation of the lower part of the extrahepatic bile duct. *Gut and Liver* 2017; 11(1): 149-155.
10. Adachi H, Sakamaki K, Nishii T, Yamamoto T, Nagashima T, Ishikawa Y, Ando K, Yamanaka K, Watanabe K, Kumakiri Y, Tsuboi M, Maehara T, Nakayama H, Masuda M. Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: a propensity score matching study. *Journal of Thoracic Oncology* 2017; 12(1): 85-93.
 11. Kiyokuni M, Konishi M, Sakamaki K, Kawashima C, Narikawa M, Doi H, Iwata K, Tomari S, Nakayama N, Komura N, Mitsuhashi T, Yano H, Sugano T, Ishigami T, Endo T, Ishikawa T, Yamanaka T, Kimura K. Beneficial effect of early infusion of landiolol, a very short-acting beta-1 adrenergic receptor blocker, on reperfusion status in acute myocardial infarction. *International Journal of Cardiology* 2016; 221: 321-326.
 12. Kawahara T, Sakamaki K, Ito H, Kuroda S, Terao H, Makiyama K, Uemura H, Yao M, Miyamoto H, Matsuzaki J. Developing a preoperative predictive model for ureteral length for ureteral stent insertion. *BMC Urology* 2016; 16(1): 70.
 13. Oshiro H, Czerniak BA, Sakamaki K, Tsuta K, Bondaruk J, Keyhani A, Dinney CP, Nagai T, Kamat AM. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. *Medicine* 2016; 95(31): e4500.
 14. Sakamaki K, Kamiura T, Morita Y, Iba K, Yoshida S, Wakana A, Tsuchiya S, Fukimbara S, Suganami H. Current practice on multiplicity adjustment and sample size calculation in multi-arm clinical trials: an industry survey in Japan. *Therapeutic Innovation & Regulatory Science* 2016; 50(6): 846-852.
 15. Inoue M, Yamane S, Sato S, Sakamaki K, Arakawa A, Kadonosono K. Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. *American Journal of Ophthalmology* 2016; 169: 95-103.
 16. Ishikawa T, Sakamaki K, Narui K, Kaise H, Tsugawa K, Ichikawa Y, Mukai H. Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study. *Japanese Journal of Clinical Oncology* 2016; 46(7): 692-695.
 17. Taira N, Fujisawa T, Araki K, Iwamoto T, Sakamaki K, Takahashi M, Aihara T, Mukai H. Cohort study of secondary endocrine therapy in metastatic breast cancer with a poor response to initial endocrine therapy. *Journal of Clinical Trials* 2016; 6: 1000260.
 18. Kobayashi S, Inoue M, Yamane S, Sakamaki K, Arakawa A, Kadonosono K. Long-term outcomes after preoperative intravitreal injection of bevacizumab before trabeculectomy for neovascular glaucoma. *Journal of Glaucoma* 2016; 25(3): 281-284.

19. Miyoshi Y, Uemura H, Umemoto S, [Sakamaki K](#), Taguri M, Suzuki K, Shibata Y, Masumori N, Ichikawa T, Mizokami A, Sugimura Y, Nonomura N, Sakai H, Honma S, Harada M Kubota Y. Low serum dehydroepiandrosterone examined by liquid chromatography - tandem mass spectrometry correlates with poor prognosis in hormone - naïve prostate cancer. *The Prostate* 2016; 76(4): 376-382.
20. Kawahara T, Furuya K, Nakamura M, [Sakamaki K](#), Osaka K, Ito H, Ito Y, Izumi K, Ohtake S, Miyoshi Y, Makiyama K, Nakaigawa N, Yamanaka T, Miyamoto H, Yao M, Uemura H. Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. *BMC Cancer* 2016; 16(1): 1.
21. Numata K, Oshima T, [Sakamaki K](#), Yoshihara K, Aoyama T, Hayashi T, Yamada T, Sato T, Cho H, Shiozawa M, Yoshikawa T, Rino Y, Kunisaki C, Akaike M, Imada M, Masuda M. Clinical significance of IGF1R gene expression in patients with stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1. *Journal of Cancer Research and Clinical Oncology* 2016; 142(2): 415-422.
22. Kozuki T, Nogami N, Kitajima H, Iwasawa S, Sakaida E, Takiguchi Y, Ikeda S, Yoshida M, Kato T, Miyamoto S, [Sakamaki K](#), Shinkai T, Watanabe K. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015. *BMC Cancer* 2016; 16(1): 1.
23. Watanabe K, Tsuboi M, [Sakamaki K](#), Nishii T, Yamamoto T, Nagashima T, Ando K, Ishikawa Y, Woo T, Adachi H, Kumakiri Y, Maehara T, Nakayama H, Kumakiri Y. Postoperative follow-up strategy based on recurrence dynamics for non-small-cell lung cancer. *European Journal of Cardio-Thoracic Surgery* 2016; 49(6): 1624-1631.
24. Ogino I, Watanabe S, Iwahashi N, Kosuge M, [Sakamaki K](#), Kunisaki C, Kimura K. Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer. *Strahlentherapie und Onkologie* 2016; 192(6): 359-367.
25. Enomoto K, Aoki S, Toma R, Fujiwara K, [Sakamaki K](#), Hirahara F. Pregnancy outcomes based on pre-pregnancy body mass index in Japanese women. *PLoS One* 2016; 11(6): e0157081.
26. Hirata G, Aoki S, [Sakamaki K](#), Takahashi T, Hirahara F, Ishikawa H. Clinical characteristics of mirror syndrome: a comparison of 10 cases of mirror syndrome with non-mirror syndrome fetal hydrops cases. *The Journal of Maternal-Fetal & Neonatal Medicine* 2016; 29(16): 2630-2634.
27. Kuroda S, Ito H, [Sakamaki K](#), Tabei T, Kawahara T, Terao H, Fujikawa A, Makiyama K, Yao M, Matsuzaki J. Development and internal validation of a classification system for predicting success rates after endoscopic combined intrarenal surgery in the modified Valdivia position for large renal stones. *Urology* 2015; 86(4): 697-702.
28. Hatayama T, Morita S, [Sakamaki K](#). Bayesian response adaptive randomization using longitudinal outcomes. *Pharmaceutical Statistics* 2015; 14(5): 369-376.

29. Morita S, [Sakamaki K](#), Yin G. Detecting overall survival benefit derived from survival postprogression rather than progression-free survival. *Journal of the National Cancer Institute* 2015; 107(8): djv133.
30. Kataoka S, Gohbara M, Iwahashi N, [Sakamaki K](#), Nakachi T, Akiyama E, Maejima N, Tsukahara K, Hibi K, Kosuge M, Ebina T, Umemura S, Kimura K. Glycemic variability on continuous glucose monitoring system predicts rapid progression of non-culprit lesions in patients with acute coronary syndrome. *Circulation Journal* 2015; 79(10): 2246-2254.
31. Akashita S, Tachibana Y, [Sakamaki K](#), Sogawa K, Inoue T. Detection of pure ground-glass nodules in the lung by low-dose multi-detector computed tomography, with use of an iterative reconstruction method: a comparison with conventional image reconstruction by the filtered back-projection method. *Japanese Journal of Radiology* 2015; 33(3): 113-121.
32. Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nagai K, Nakashima K, Ushio R, Ikeda M, [Sakamaki K](#), Yoshiyama T, Kaneko T. Sensitivity and specificity of Cobas TaqMan MTB real-time polymerase chain reaction for culture-proven Mycobacterium tuberculosis: meta-analysis of 26999 specimens from 17 Studies. *Scientific Reports* 2015; 5: 18113.
33. Nagai T, Oshiro H, Sagawa Y, [Sakamaki K](#), Terauchi F, Nagao T. Pathological characterization of ovarian cancer patients who underwent debulking surgery in combination with diaphragmatic surgery: a cross-sectional study. *Medicine* 2015; 94(50): e2296.
34. Kawahara T, Fukui S, [Sakamaki K](#), Ito Y, Ito H, Kobayashi N, Izumi K, Yokomizo Y, Miyoshi Y, Makiyama K, Nakaigawa N, Yamanaka T, Yao M, Miyamoto H, Uemura H. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. *Oncotarget* 2015; 6(31): 32169.
35. Masuda M, Sato T, [Sakamaki K](#), Kudo M, Kaneko T, Ishigatsumo Y. The effectiveness of sputum pH analysis in the prediction of response to therapy in patients with pulmonary tuberculosis. *PeerJ* 2015; 3: e1448.
36. Takagi Y, Hosomi Y, Oshita F, Okamoto H, Seki N, Minato K, Aono H, Yamada K, Okuma Y, Hida N, Sakamoto T, Miura Y, Yomota M, Satoh A, Kunitoh H, [Sakamaki K](#), Shibuya M, Sakamoto T. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014. *BMC Cancer* 2015; 15(1): 1.
37. Fujikawa H, [Sakamaki K](#), Kawabe T, Hayashi T, Aoyama T, Sato T, Oshima T, Rino Y, Morita S, Masuda M, Ogata T, Cho H, Yoshikawa T. A New statistical model identified two-thirds of clinical T1 gastric cancers as possible candidates for endoscopic treatment. *Annals of Surgical Oncology* 2015; 22(7): 1-6.
38. Gohbara M, Iwahashi N, Kataoka S, Hayakawa Y, [Sakamaki K](#), Akiyama E, Maejima N,

- Tsukahara K, Hibi K, Kosuge M, Ebina T, Umemura S, Kimura K. Glycemic variability determined by continuous glucose monitoring system predicts left ventricular remodeling in patients with a first ST-segment elevation myocardial infarction. *Circulation Journal* 2015; 79(5): 1092-1099.
39. Oshiro H, Miura M, Lobe H, Kudo T, Shimazu Y, Aoba T, Okudela K, Nagahama K, Sakamaki K, Yoshida M, Nagao T, Nakaya T, Kurata A, Ohtani O. Lymphatic stomata in the adult human pulmonary ligament. *Lymphatic Research and Biology* 2015; 13(2): 137-145.
 40. Konishi M, Akiyama E, Suzuki H, Iwahashi N, Maejima N, Tsukahara K, Hibi K, Kosuge M, Ebina T, Sakamaki K, Matsuzawa Y, Endo M, Umemura S, Kimura K. Hypercapnia in patients with acute heart failure. *ESC Heart Failure* 2015; 2(1): 12-19.
 41. Ito H, Sakamaki K, Kawahara T, Terao H, Yasuda K, Kuroda S, Yao M, Kubota Y, Matsuzaki J. Development and internal validation of a nomogram for predicting stone free status following flexible ureteroscopy for renal stones. *BJU International* 2015; 115(3): 446-51.
 42. Ide H, Yamagishi SI, Lu Y, Sakamaki K, Nakajima A, Horiuchi A, Kitamura K, Hisasue S, Muto S, Yamaguchi R, Horie S. Circulating pigment epithelium-derived factor (PEDF) is associated with pathological grade of prostate cancer. *Anticancer Research* 2015; 35(3): 1703-1708.
 43. Akiyama E, Sugiyama S, Matsubara J, Kurokawa H, Konishi M, Nozaki T, Ohba K, Fujisue K, Maeda H, Sakamoto K, Sugamura K, Sumida H, Jinnouchi H, Sakamaki K, Morita S, Kimura K, Umemura S, Ogawa, H. Decreased plasma levels of active glucagon-like peptide-1 in coronary artery disease. *Journal of the American College of Cardiology* 2015; 65(7): 754-755.
 44. Kondo M, Morimoto M, Ishii T, Nozaki A, Fukuda H, Numata K, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Shibuya A, Okuse C, Suzuki M, Sakamaki K, Morita S, Maeda S, Tanaka K. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients not responsive to transarterial chemoembolization: a propensity score based weighting. *Journal of Digestive Diseases* 2015; 272(3): 598-604.
 45. Yamamoto S, Chishima T, Mastubara Y, Adachi S, Harada F, Toda Y, Arioka H, Hasegawa N, Kakuta Y, Sakamaki K. Variability in measuring the Ki-67 labeling index in patients with breast cancer. *Clinical Breast Cancer* 2015; 15(1): e35-e39.
 46. Taniguchi H, Aoki S, Sakamaki K, Kurasawa K, Okuda M, Takahashi T, Hirahara F. Circumvallate placenta: associated clinical manifestations and complications-a retrospective study. *Obstetrics and Gynecology International* 2014; 31: 1-5.
 47. Miyoshi Y, Uemura H, Umemoto S, Sakamaki K, Morita S, Suzuki K, Shibata Y, Masumori N, Ichikawa T, Mizokami A, Sugimura Y, Nonomura N, Sakai H, Homma S, Harada, Kubota Y. High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients. *BMC Cancer* 2014; 14(1): 717.
 48. Fukuda H, Numata K, Moriya S, Shimoyama Y, Ishii T, Nozaki A, Kondo M, Morimoto M,

- Maeda S, Sakamaki K, Morita S, Tanaka K. Hepatocellular carcinoma: concomitant Sorafenib promotes necrosis after radiofrequency ablation—propensity score matching analysis. *Radiology* 2014; 272(2): 598-604.
49. Miwa H, Numata K, Sugimori K, Kaneko T, Sakamaki K, Ueda M, Fukuda H, Tanaka K, Maeda S. Differential diagnosis of solid pancreatic lesions using contrast-enhanced three-dimensional ultrasonography. *Abdominal Imaging* 2014; 39(5): 988-999.
50. Mima K, Beppu T, Ishiko T, Chikamoto A, Nakagawa S, Hayashi H, Watanabe M, Sakamaki K, Baba H. Preoperative serum hyaluronic acid level as a prognostic factor in patients undergoing hepatic resection for hepatocellular carcinoma. *British Journal of Surgery* 2014; 101(3): 269-276.
51. Konishi M, Matsuzawa Y, Suzuki H, Akiyama E, Iwahashi N, Maejima N, Endo M, Tsukahara K, Hibi K, Kosuge M, Ebina T, Sakamaki K, Morita S, Umemura S, Kimura K. Higher level at admission and subsequent decline in hemoglobin in patients with acute pulmonary edema. *Circulation Journal* 2014; 78(4): 896-902.
52. Baba Y, Watanabe M, Murata A, Shigaki H, Miyake K, Ishimoto T, Iwatsuki M, Iwagami S, Yoshida N, Oki E, Sakamaki K, Nakao M, Baba H. LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma. *Clinical Cancer Research* 2014; 20(5): 1114-1124.
53. Honjo M, Moriyasu F, Sugimoto K, Oshiro H, Sakamaki K, Kasuya K, Nagai T, Tsuchida A, Imai Y. Relationship between the liver tissue shear modulus and histopathologic findings analyzed by intraoperative shear wave elastography and digital microscopically assisted morphometry in patients with hepatocellular carcinoma. *Journal of Ultrasound in Medicine* 2014; 33(1): 61-71.
54. Sasaki T, Kunisaki R, Kinoshita H, Yamamoto H, Kimura H, Hanzawa A, Shibata N, Yonezawa H, Miyajima E, Sakamaki K, Numata K, Tanaka K, Maeda S. Use of color Doppler ultrasonography for evaluating vascularity of small intestinal lesions in Crohn's disease: correlation with endoscopic and surgical macroscopic findings. *Scandinavian Journal of Gastroenterology* 2014; 49(3): 295-301.
55. Ide H, Terado Y, Sakamaki K, Inoue M, Nakajima A, Lu Y, Hisasue S, Yamaguchi R, Muto S, Horie S. Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer. *Prostate International* 2013; 1(3): 109-112.
56. Fujita R, Iimuro S, Shinozaki T, Sakamaki K, Uemura Y, Takeuchi A, Matsuyama Y, Ohashi Y. Decreased duration of acute upper respiratory tract infections with daily intake of fermented milk: A multicenter, double-blinded, randomized comparative study in users of day care facilities for the elderly population. *American Journal of Infection Control* 2013; 41(12): 1231-1235.

57. Tsuboi S, Miyashita T, Yamaguchi Y, Yamamoto Y, Sakamaki K, Goto T. The TaperGuard™ endotracheal tube intracuff pressure increase is less than that of the Hi-Lo™ tube during nitrous oxide exposure: a model trachea study. *Anesthesia & Analgesia* 2013; 116(3): 609-612.
58. Konishi M, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Matsubara J, Sakamoto K, Nagayoshi Y, Sumida H, Akiyama E, Matsuzawa Y, Sakamaki K, Morita S, Kimura K, Umemura S, Ogawa H. Basal and ischemia-induced transcardiac troponin release into the coronary circulation in patients with suspected coronary artery disease. *PLoS One* 2013; 8(4): e60163.
59. Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, Iwatsuki M, Sakamaki K, Ohashi Y, Baba H. LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. *Annals of Surgery* 2013; 257(3): 449-455.
60. Matsumura N, Utsumi K, Sakamaki K, Watabe M, Aoyama K, Nakaki T. Anticonvulsant action of indazole. *Epilepsy Research* 2013; 104(3): 203-216.
61. Nakamura M, Tanaka F, Nakajima S, Honma M, Sakai T, Kawakami M, Endo H, Onodera M, Niiyama M, Komatsu T, Sakamaki K, Onoda T, Sakata K, Morino Y, Takahashi T, Makita S. Comparison of the incidence of acute decompensated heart failure before and after the major tsunami in northeast Japan. *The American Journal of Cardiology* 2012; 110(12): 1856-1860.
62. Onodera M, Nakamura M, Tanaka F, Takahashi T, Makita S, Ishisone T, Ishibashi Y, Itai K, Onoda T, Ohsawa M, Tanno K, Sakata K, Omama S, Ogasawara K, Ogawa A, Kuribayashi T, Sakamaki K, Okayama A. Plasma B-type natriuretic peptide is useful for cardiovascular risk assessment in community-based diabetes subjects: comparison with albuminuria. *International Heart Journal* 2012; 53(3): 176-181.
63. Sakurai T, Iimuro S, Sakamaki K, Umegaki H, Araki A, Ohashi Y, Ito H; Japanese Elderly Diabetes Intervention Trial Study Group. Risk factors for a 6-year decline in physical disability and functional limitations among elderly people with type 2 diabetes in the Japanese elderly diabetes intervention trial. *Geriatrics & Gerontology International* 2012; 12(s1): 117-126.
64. Kumagai K, Sakai K, Kusayama Y, Akamatsu Y, Sakamaki K, Morita S, Sasaki T, Saito T, Sakai T. The extent of degeneration of cruciate ligament is associated with chondrogenic differentiation in patients with osteoarthritis of the knee. *Osteoarthritis and Cartilage* 2012; 20(11): 1258-1267.
65. Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, Hama T, Masuda H, Horie S. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. *The Prostate* 2010; 70(10): 1127-1133.
66. 坂巻顕太郎. 構造化仮説群の多重性制御法 1 (Gatekeeping 法). *計量生物学* 2015; 36(2): S147-S164.
67. 吉田征太郎, 坂巻顕太郎. 臨床試験における Gatekeeping 法の適用例. *計量生物学* 2015;

36(2): S165-S171.

68. 武田健太郎, 大庭真梨, 柿爪智行, 坂巻顕太郎, 田栗正隆, 森田智視. 臨床試験におけるヒストリカルコントロールデータの利用. *計量生物学* 2015; 36(1): 25-50.

Non-peer reviewed publications

1. Sakamaki K, Yamanaka T. Primer of surgical clinical trials. *Nihon Geka Gakkai Zasshi* 2016; 117(1): 33-39. (in Japanese)
2. 坂巻顕太郎, 山中竹春. 臨床研究デザインの構築. *臨床外科* 2016; 71(5): 536-540.
3. 坂巻顕太郎. 診断に関する基本的事項. *病理と臨床* 2015; 33: 777-781.
4. 大橋靖雄, 坂巻顕太郎. 統計の問題 (ROC 曲線, logistic 回帰分析, 競合項目など). *動脈硬化予防* 2009; 8: 44-56.

PRESENTATIONS

1. Oshima T, Miyagi Y, Kimura Y, Sakamaki K, Yamanaka S, Oue N, Aoyama T, Sato T, Cho H, Shiozawa M, Yoshikawa T, Rino Y, Yasui W, Imada T, Masuda M. Search for a combination of risk stratification markers for recurrence after curative resection of gastric cancer. AACR Annual Meeting 2017, Washington, DC, April 1-5, 2017. (Abstract: *Cancer Research* 2017; 77(13): abstr 5725)
2. Sakamaki K, Kito Y, Izawa N, Tsuda T, Morita S, Yamazaki K, Boku N, Muro K, Hyodo I. Predictability of survival outcome by early tumor shrinkage (ETS) at 8 weeks with cutoff value of 20% in metastatic colorectal cancer (mCRC) patients treated with mFOLFOX6 plus bevacizumab (bev) or FOLFIRI plus bev as first-line chemotherapy (1st-CTx): Validation in the phase III WJOG4407G trial. 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, January 19-21, 2017. (Abstract: *Journal of Clinical Oncology* 2017; 35(4S): abstr 729)
3. Fujitani K, Ando M, Sakamaki K, Terashima M, Kawabata R, Ito Y, Yoshikawa T, Kondo M, Kodera Y, Kaji M, Oka Y, Imamura H, Kawada J, Takagane A, Shimada H, Tanizawa Y, Yamanaka T, Morita S, Ninomiya M, Yoshida K. A prospective multicenter observational study of surgical palliation examining postoperative quality of life in patients treated for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, January 19-21, 2017. (Abstract: *Journal of Clinical Oncology* 2017; 35(4S): abstr 6)
4. Sakamaki K. A group sequential closed testing procedure based on Simes test for clinical trials with multiple objectives. The 10th ICSA International Conference, Shanghai, China, December 19-22, 2016. (Abstract:)
5. Watanabe K, Sakamaki K, Nishii T, Gorai A, Yamamoto T, Nagashima T, Ando K, Ishikawa Y,

- Woo T, Adachi H, Kumakiri Y, Maehara T, Nakayama H, Masuda M. Alternative follow-up methods based on recurrence patterns after surgery for non-small cell lung cancer. IASLC 17th World Conference on Lung Cancer, Vienna, Austria, December 4-7 2016. (Abstract: *Journal of Clinical Oncology* 2017; 12(1): abstr OA01.07)
6. Nishikawa K, Yoshikawa T, Fujitani K, Tanabe K, Ito S, Matsui T, Miki A, Nemoto H, Sakamaki K, Cho H, Fukunaga T, Kimura Y, Hirabayashi N. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer. ESMO 2016 Congress, Copenhagen, Denmark, October 7-11, 2016. (Abstract: *Annals of Oncology* 2016; 27(6): 640P)
 7. Ishikawa T, Narui K, Kaise H, Tsugawa K, Ichikawa Y, Sakamaki K, Mukai H. Current Status of Management of Febrile Neutropenia in Chemotherapy for Solid Tumors. The Japanese Society of Medical Oncology 2016 Annual Meeting, Kobe, Japan, July 28-30, 2016. (Abstract: *Annals of Oncology* 2016; 27(7))
 8. Matsuzaki K, Ito Y, Fukuda M, Sakamaki K, Ando M, Kojima Y, Furuya N, Tsuda T, Minatogawa H, Ichikawa Y, Ohta I, Takei S, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S, Yamanaka T, Boku N, Nakajima ET. Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetron in high emetogenic chemotherapy. ASCO Annual Meeting 2016, Chicago, IL, June 3-7, 2016. (Abstract:)
 9. Noritake M, Zenjiro S, Sugae S, Tanabe M, Sakamaki K, Inoue T, Ishikawa T. Evaluation of the response to breast cancer neoadjuvant chemotherapy using 18F-FDG positron emission mammography compared with whole-body 18F-FDG PET. SNMMI (The Society of Nuclear Medicine & Molecular Imaging) 2016 Annual Meeting, San Diego, CA, June 11-15, 2016. (Abstract: *Journal of Nuclear Medicine* 2016; 57(2): 1485)
 10. Hasegawa T, Sakamaki K, Koiwa F, Akizawa T. Clinical prediction models for progression of chronic kidney disease to end stage kidney failure under predialysis nephrology care: results from The Chronic Kidney Disease Japan Cohort study. 53rd ERA-EDTA Congress, Vienna, Austria, May 21-24, 2016. (Abstract: *Nephrology Dialysis Transplantation* 2016 31(1): i439.)
 11. Murakami M, Kanemura T, Haga A, Kubota R, Yaguchi K, Nishio M, Tsuda S, Ogashiwa T, Kogure Y, Kasahara K, Hirai K, Fukuno Y, Jin M, Hanzawa A, Yonezawa H, Sakamaki K, Numata K, Kimura H, Kunisaki R. Usefulness of ultrasonography in the assessment of postoperative recurrence of Crohn's disease. 11th Congress of ECCO, Amsterdam, Netherlands, March 16-19, 2016. (Abstract P414)
 12. Yoshikawa T, Hiki N, Sakamaki K, Ito S, Fujitani K, Takiguchi N, Kawashima Y, Nishikawa K, Sasako M, Ida S, Aoyama T, Honda M, Sato T, Nunobe S, Ogata T, Cho H. Effects of

- perioperative enteral EPA-enriched immunonutrition on meaningful loss of lean body mass after total gastrectomy for gastric cancer: Post hoc analysis of a phase III study. 2016 Gastrointestinal Cancers Symposium, January 21-23, 2016. (Abstract: *ASCO Annual Meeting Proceedings* 2016; 34(4): 85)
13. Fujita Y, Kagawa K, Fujisawa T, Fujisawa N, Sekino Y, Hosono K, Matsushashi N, Sakamaki K, Nakajima A, Kubota K. Feasibility of endoscopic papillary large balloon dilation in patients with difficult bile duct stones and without dilatation of the lower part of the extra-hepatic bile duct. UEG Week 2015, Barcelona, Spain, October 24-28, 2015. (Abstract:)
 14. Hiki N, Yoshikawa T, Sakamaki K, Ito S, Fujitani K, Takiguchi N, Kawashima Y, Nishikawa K, Sasako M, Ida S, Aoyama T, Honda M, Sato T, Nunobe S, Cho H. A phase III trial to confirm preventing effects of perioperative enteral EPA-enriched immunonutrition on body weight loss after total gastrectomy for gastric cancer. European Society for Medical Oncology 2015 Congress, Vienna, Austria, September 25-29, 2015. (Abstract:)
 15. Kito Y, Sakamaki K, Yamazaki K, Izawa N, Tsuda T, Morita S, Boku N. Evaluation timing and cutoff value of tumor size (TS) ratio by using tumor growth inhibition (TGI) model to predict overall survival (OS) in metastatic colorectal cancer (mCRC) patients received first-line chemotherapy (CTx). European Society for Medical Oncology 2015 Congress, Vienna, Austria, September 25-29, 2015. (Abstract:)
 16. Yoshikawa T, Fujitani K, Nishikawa K, Tanabe K, Ito S, Matsui T, Miki A, Nemoto H, Sakamaki K, Cho H, Fukunaga T, Kimura Y, Hirabayashi N. Comparison of chemotherapy-related toxicities in a randomized 2X2 phase II trial comparing two and four courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer. European Society for Medical Oncology 2015 Congress, Vienna, Austria, September 25-29, 2015. (Abstract:)
 17. Sakamaki K. Blinded Sample Size Recalculation for Survival Data. 2015 Joint Statistical Meetings, Seattle, WA, August 8-13, 2015. Abstract #372.
 18. Oshima T, Sakamaki K, Miyagi Y, Yoshikawa T, Shiozawa M, Cho H, Rino Y, Kunisaki C, Tsuburaya A, Imada T, Masuda M. Stratification markers for the risk of recurrence after curative resection of stage II or III gastric cancer and potential clinical applications. 2015 ASCO Annual Meeting, Chicago, IL, May 29-June 2, 2015. (Abstract: *Journal of Clinical Oncology* 2015; 33; abstr 11040)
 19. Tsukahara K, Miyauchi K, Sakamaki K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y, Kimura K, Origasa H, Morino Y, Tsutsui H, Isshiki T, Daida H. Impact of bleeding complications on clinical outcomes in Japanese patients with acute coronary syndromes: an analysis from the PACIFIC registry. The 79th Annual Scientific Meeting of the Japanese Circulation Society, Osaka, Japan, April 24-26, 2015. (Abstract:)

20. Oshima T, [Sakamaki K](#), Miyagi Y, Shiozawa M, Kunisaki C, Yoshikawa T, Rino Y, Imada T, Masuda M. Assessment of recurrence risk stratification markers after curative resection of stage II or III gastric cancer and potential clinical applications. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, April 18-22, 2015. (Abstract: *Cancer Research* 2015; 75(15): 3413)
21. Oshiro H, Czerniak B, [Sakamaki K](#), Tsuta K, Bondaruk J, Keyhani A, Dinney C, Nagai T, Kamat A. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measurement of Ki67 and apoptosis indices in human bladder cancers. American Urological Association Annual Meeting 2015, New Orleans, LA, May 15–19, 2015. (Abstract: *The Journal of Urology* 193: e537)
22. Miyoshi Y, Umemoto S, Uemura H, Shibata Y, [Sakamaki K](#), Honma S, Suzuki K, Kubota Y. High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor prognosis factors in prostate cancer patients. European Society for Medical Oncology 2014 Congress, Madrid, Spain, September 26-30, 2014. (Abstract: *Annals of Oncology* 2014; 25: iv269)
23. Ito H, [Sakamaki K](#), Kawahara T, Terao H, Yasuda K, Kuroda S, Matsuzaki M, Yao Y, Kubota Y. Development and internal validation of a preoperative nomogram for predicting the outcome of flexible ureteroscopy for the treatment of renal stone. 29th Annual European Association of Urology congress, Stockholm, Sweden, April 11-15, 2014. (Abstract: *European Urology* 2014; 13: e926)
24. [Sakamaki K](#). Mixture procedures using weighted multiple testing procedures. 2014 Joint Statistical Meetings, Boston, USA, August 2-7, 2014. (Abstract #563)
25. [Sakamaki K](#). A comparison of group sequential testing for clinical trials with multiple survival endpoints. XXVIIth International Biometrics Conference 2014, Florence, Italy, July 6-11, 2014. (Abstract #54)
26. Fujikawa H, [Sakamaki K](#), Kawabe T, Hayashi T, Aoyama T, Wakasugi T, Yoshikawa T. Prediction of nodal metastasis in clinical T1 gastric cancer. 2014 Gastrointestinal Cancers Symposium, San Francisco, CA, January 16-18, 2014. (Abstract: *Journal of Clinical Oncology* 2014; 32(3): 2318)
27. Ide H, Yamagishi S, Lu Y, [Sakamaki K](#), Yamaguchi R, Muto S, Horie S. The circulating pigment epithelium derived factor (PEDF) is associated with pathological grade of prostate cancer. American Urological Association Annual Meeting 2014, Orlando, FL, May 16-21, 2014 (Abstract: *The Journal of Urology* 2014: 191(4); e857-e858)
28. Konishi M, Matsuzawa Y, Suzuki H, Akiyama E, Iwahashi N, Hibi K, Kosuge M, Ebina T, [Sakamaki K](#), Morita K, Umemura S, Kimura K. Early hemoglobin decrease in heart failure with acute pulmonary edema. American Heart Association Scientific sessions 2013, Dallas, TX,

- November 16-20 2013. (Abstract #13858)
29. Sakamaki K. Testing composite and mortality endpoints in group sequential tests. 34th Annual Conference of the International Society for Clinical Biostatistics, Munich, Germany, August 25-29, 2013. (Abstract P55)
 30. Sakamaki K. A Group sequential method using Hochberg procedure for clinical trials with multiple primary endpoints. 2013 Joint Statistical Meetings, Montreal, Canada, August 3-8, 2013. (Abstract #599)
 31. Sakamaki K., Matsuyama Y, Ohashi Y. Flexible multiple testing procedures based on resampling methods for gatekeeping applications. 2012 Joint Statistical Meetings, San Diego, CA, July 28-August 2, 2012. (Abstract #306148)
 32. Sakamaki K., Matsuyama Y, Ohashi Y. Graphical procedures for gatekeeping applications. XXVIth International Biometrics Conference 2012, Kobe, Japan, August 26-31, 2012. (Abstract P-3-20)
 33. Ohsumi S, Inaji H, Shigematsu H, Akashi-Tanaka S, Sato N, Takahashi K, Oura S, Sakamaki K. Factors associated with ipsilateral breast tumor recurrence in breast cancer patients treated with breast conserving surgery and radiotherapy after preoperative chemotherapy. 33rd San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010. (Abstract P4-10-05)

SYMPOSIUM/SEMINAR/WORKSHOP

1. Sakamaki K. Study duration extension using blinded survival data. Wiener Biometrische Sektion Herbstseminar 2015 (DVANCES IN TRIAL DESIGN), Vienna, Austria, October 7, 2015.
2. Sakamaki K. A step-up procedure for testing multiple endpoints in group sequential trials. Austria-Japan Joint Statistics Workshop on "Innovative Clinical Trial Designs and Personalized Medicine for Accelerating Medical Product Development", Osaka, Japan, March 25-27, 2015.
3. Sakamaki K. Gatekeeping procedure. The Biometric society of Japan Seminar 2014, Kyoto, Japan, December 19-20, 2014. (in Japanese)
4. Sakamaki K. Problem of evaluating predictive ability by receiver operating characteristics curve. The Japan Arteriosclerosis Longitudinal Study (JALS) group statistical analysis tutorial. Tokyo, Japan, September 10, 2010. (in Japanese)